CTRI/2021/11/038335Active, not recruiting未知
An Open Label, Randomized, Parallel, Multi-center, Five-Arm, Comparative Clinical Study to Assess the Efficacy and Safety of H-15 (Boswellia serrata) Soft Gel Capsules and Sallaki tablets 400 mg in Comparison with Standard of Care (SOC) in Patients Suffering from Mild to Moderate Bronchial Asthma
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
- Sponsor
- Gufic Biosciences Limited
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Male/female of >=18 and <=60 years of age
- •2.Patient who can and willing to provide written Informed Consent
- •3.Patient with an established diagnosis of mild to moderate bronchial asthma (FEV1 between 60 and 80%)
- •4.Patient with mild asthma under the treatment with low dose of Inhaled Corticosteroids (ICS) ICS-formoterol alone and patients with moderate asthma under the treatment of low or medium dose ICS-LABA (Long-Acting Beta-Agonist)
- •5.Patient with ACT (Asthma control test) score Ë?19
- •6.Female of childbearing potential must have a negative pregnancy test and be non-lactating at screening visit
- •7.Patient/ patientâ??s legally acceptable representative understands and can comply with clinical trial protocol requirements
Exclusion Criteria
- •1.Patient Ë? 18 or Ë? 60 years of age
- •2.Pregnant and/or nursing woman
- •3.Patient with severe or unstable bronchial asthma or having acute asthmatic attack at the time of enrolment
- •4.Patient with a clinically relevant respiratory tract infection in the four weeks prior to enrolment
- •5.Patient with any other clinically significant illness
- •6.Patient with a history of hypersensitivity to any of the components of the study medications
- •7.Patient who has participated in another trial with an investigational drug within 1 month prior to this trial.
- •8.Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol
Investigators
Similar Trials
Completed
Phase 3
Study to evaluate the efficacy and safety of Tranexamic acid spray 10% w/v comparing with placebo in patients undergoing dental extraction.CTRI/2022/03/041099Shilpa Medicare Limited80
Completed
Phase 1
Triamcinolone Hexacetonide (THA) 20mg/ml injection in patients with knee osteoarthritis.CTRI/2020/12/029771Abbott Healthcare Pvt Ltd44
Active, not recruiting
Phase 1
Bendamustine, thalidomide and dexamethasone in relapsed/refractory myelomaEUCTR2010-021451-12-GBniversity of Leeds95
Active, not recruiting
Not Applicable
Pediatric FeverfeverEUCTR2010-024387-17-PLCumberland Pharmaceuticals Inc.200
Not yet recruiting
Unknown
Effect of paclitaxel protein-bound particles for injectable suspension in breast cancer patients.CTRI/2024/04/065727Dr Reddys Laboratories Limited
